Shilpa Mediacare in focus after company receives Form 483 from USFDA

Shares of the Hyderabad-based Shilpa Medicare will be in focus in trade on Monday after the company post market hours on Friday informed stock exchanges that its subsidiary received a Form 483 from the United States Food and Drug Administration (USFDA) for its Raichur plant with one observation.

Form 483 issued by the USFDA to a company to alert a company about potentially problematic areas that require attention.

Shilpa Medicare in a notification said that the Form 483 was issued by the USFDA after inspecting Unit-1 of Shilpa Pharma Lifesciences Limited, located at Raichur from March 3-7, 2025. " On conclusion of inspection, we received 1 (one) observation in form 483, which is procedural in nature," the company said in a stock exchange filing.

"The company will closely work with the agency and remain committed to address this observation comprehensively within stipulated time," Shilpa Medicare added

Shilpa Medicare shares closed 1.68% higher at ₹671.95 on the BSE on Friday. The stock has so far this year fallen 17.68% underperforming the Nifty Pharma index which has declined 13%.

Meanwhile, Sun Pharma, Lupin and Alembic Pharma from the pharma space will also be in focus today.